| Revenue growth | +17.1% YoY Q2; Ex-US led |
|---|---|
| Margins | Gross margin 56.0% (-180bps); EBITDA margin 17.6% (-140bps) |
| Demand visibility | H2 stronger on launches; Ex-US pipeline strong |
| Management confidence | Ambition intact; US timing changed |
Growth
Q2 Ex-US +31% to ₹6,963m; US +9% to ₹6,855m. H1 revenue +15.1%, EBITDA +6.9%, operational PAT +9.8%.
Outlook
Net debt/EBITDA to stabilise by year-end; H2 stronger on launches; US $375m FY28 target shifted beyond FY28.
Risks
Gross margin down 180bps; EBITDA margin down 140bps; net debt up ₹2,114m in H1; cash cycle 137 days; US quotas constrain.
Last quarter's promises, checked
Delivered
- Ex-US grow faster than co. avg → Ex-US +31% vs co. +17.1% (= BEAT)
- 3 launches from Q2 onward → 3 US launches in Q2 (= BEAT)
Partly delivered
- ~10 launches by 31-Mar-27 → 3 in Q2, 2 qtrs left (= PARTIAL)
- $7m Ex-US spillover recovery → Ex-US ₹5,875m→₹6,963m QoQ, $ not disclosed (= PARTIAL)
Missed
- US $375m by FY28 → pushed beyond FY28 (= MISS)
- Gross margin 58-60% → 56.0% (= MISS)
- Net debt reduction, ND/EBITDA 1.52x → ND ₹14,246m→₹16,479m, 1.72x (= MISS)
Investor Presentation filed with NSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,100.90
- Market cap
- ₹10,147 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.5×Sector 46.1×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY
Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.
Strides Pharma Science Other Announcement
Strides Pharma Science Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.